STORY AT-A-GLANCE
- In the early 2000s, David Martin, Ph.D., founder of M-CAM International, started finding large numbers of patents that violate biological and chemical weapons laws
- In 1999, Dr. Anthony Fauci funded research to create “an infectious replication-defective recombinant coronavirus.” In 2002, Ralph Baric, Ph.D. and colleagues at the University of North Carolina, Chapel Hill, filed a patent on recombinant coronavirus, and within a year, we got the world’s first SARS outbreak
- Since 1999, at least 4,000 patents involving coronavirus have been filed, including patents detailing key features of the so-called “novel” SARS-CoV-2 virus
- The 2001 anthrax attack, which came out of medical and defense research, led to the passage of the PREP Act, which removed liability for manufacturers of emergency medical countermeasures
- The funds for entitlement programs and pensions will dry up by 2028, at which point the drug industry will go bankrupt as well. With a burgeoning population that is sick from the COVID jabs, we need to prepare new systems to care for each other
In this interview, we continue our coverage of the COVID “plandemic” by speaking to David Martin, Ph.D., who has done a phenomenal job uncovering the paper trail behind the virus now known as SARS-CoV-2. As it turns out, this is not a novel virus at all, as patents and government grants detailing key features of the virus go back two decades.
Martin finished his doctorate at the University of Virginia in 1995, after which he was hired on to the medical school faculty in radiology and orthopedic surgery. In 2006, he set up the first medical device clinical trials organization for the University of Virginia — a company called IDEAmed — which conducted medical device clinical trials for U.S. Food and Drug Administration submission. So, he has an extensive background working with FDA clinical trials.
Monitoring Biological Weapons Violations
In 1998, he founded another company called M-CAM International, which is focused on finding ways to bring intellectual property into conventional finance. M-CAM also started auditing the U.S. patent system at the request of the U.S. Congress.
In the early 2000s, M-CAM worked with the Senate Banking Committee and was a contractor for the United States Treasury to expose white collar criminal activity around intellectual property and tax fraud. In doing that work, Martin also discovered something else…
<strong>Read full story</strong> [icon name=”arrow-right” prefix=”fas”] Patents Prove COVID Fraud and Illegal Dealings